Even within single tumor types such as in breast cancer, become available.0 However, gaps remain despite the availability of targeted therapies, with persistent testing rates can vary by biomarker type. For example, variation both across and within tumor types. and FRa (80%) compared to MSI (90%) in ovarian cancer. As of December 2024, testing rates for nearly all compared to PSMA (75%) biomarkers is seen. metastatic disease (Exhibit 2). Oncologists and tumor, meaning that biomarker testing is entrenched within clinical care. Understanding the drivers behind are aligned with their clinical experience. Oncologists replicate this success in other tumor types is critical. 8 | Advancing Precision Oncology: Trends in Oncology Biomarker Testing in the U.S.